Real-time Bioprobe for Diabetes Treatments

Real-time Bioprobe for Diabetes Treatments

Author: ChemViews

The ability of a compound to treat diabetes is marked by an increase in the rate of glucose uptake in cells. This rate can be monitored by using radioisotope (14C or 3H)-labeled 2-deoxyglucose analogues—the current gold standard for determining cellular glucose uptake.

Seung Bum Park and colleagues, Seoul National University, Korea, have developed a novel bioprobe, GB2-Cy3, for real-time monitoring of glucose uptake. They synthesized a series of fluorescent glucose analogues by adding the water-soluble, cyanine-based dye, Cy3, to the α-anomeric position of ᴅ-glucose with various linkers.

GB2-Cy3 was shown to be ten times more sensitive than 2-NBDG, a leading fluorescent glucose bioprobe, and could be utilized in three different systems to monitor glucose in metabolically active C2C12 myocytes.

The real-time monitoring of glucose uptake in living cells could have significant impact for diagnosing metabolic diseases.


Leave a Reply

Your email address will not be published.